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Abstract
Patients with obsessive-compulsive disorder (OCD) show an increased error-related negativity (ERN), yet previous
studies have not controlled for medication use, which may be important given evidence linking performance mon-
itoring to neurotransmitter systems targeted by treatment, such as serotonin. In an examination of 19 unmedicated
OCD patients, 19 medicated OCD patients, 19 medicated patient controls without OCD, and 21 unmedicated healthy
controls, we found greater ERNs in OCD patients than in controls, irrespective of medication use. Severity of
generalized anxiety and depression was associated with ERN amplitude in controls but not patients. These data
confirm previous findings of an exaggerated error response in OCD, further showing that it cannot be attributed to
medication. The absence in patients of a relationship between ERN amplitude and anxiety/depression, as was found in
controls, suggests that elevated error signals in OCD may be disorder-specific.
Descriptors: Error-related negativity (ERN), Event-related potentials (ERPs), Anxiety, Anterior cingulate cortex
(ACC)
Obsessive-compulsive disorder (OCD) is characterized by intru-
sive thoughts (obsessions) and/or repetitive behaviors (compul-
sions) that are often associated with intense doubt regarding the
correctness of an act or excessive fear about the likelihood of a
bad outcome. Proposals that symptoms are related to an over-
active error detection mechanism that continually signals that
‘‘something is wrong’’ (Pitman, 1987; Schwartz, 1997) have been
supported by research identifying alterations in the neural sub-
strate for error processing in OCD. Errors elicit robust activation
in a network of brain regions including medial frontal cortex
(MFC) (Taylor, Stern, &Gehring, 2007). In particular, the error-
related negativity (ERN, or Ne) component of the event-related
brain potential (ERP), which onsets at the time of error com-
mission (Falkenstein, Hohnsbein, Hoormann, & Blanke, 1990;
Gehring, Goss, Coles, Meyer, & Donchin, 1993) and localizes to
MFC (Dehaene, Posner, & Tucker, 1994; van Veen & Carter,
2002), has emerged as an index of dysfunctional error processing
in OCD. Several groups have found an increased ERN in pa-
tients with clinical OCD (Endrass, Klawohn, Schuster, &
Kathmann, 2008; Gehring, Himle, & Nisenson, 2000; Johannes
et al., 2001; but see Nieuwenhuis, Nielen, Mol, Hajcak, & Velt-
man, 2005 for alternate finding) and undiagnosed subjects with
high ratings of OC symptoms (Hajcak & Simons, 2002).
While the error signal appears to be increased in OCD, pre-
vious studies have not always controlled for other factors that
may influence the ERN. In particular, medications such as sero-
tonin reuptake inhibitors (SRIs) are commonly used to treat pa-
tients with OCD, and many studies of error processing in OCD
have tested groups where some or all patients were taking med-
ication (Endrass et al., 2008; Gehring et al., 2000;Nieuwenhuis et
al., 2005; Ursu, Stenger, Shear, Jones, &Carter, 2003).While the
influence of dopamine in generating and/or modulating the ERN
has perhaps received the most attention (Holroyd & Coles,
2002), evidence now also links serotonergic (Fallgatter et al.,
2004) and noradrenergic systems to performancemonitoring (for
a review, see Jocham&Ullsperger, 2009), pointing to the need to
consider medication status when investigating the ERN in psy-
chiatric populations. A very few studies have examined unmed-
icated patients, but in small samples. Johannes and colleagues
(2001) found increased ERNs in 10 unmedicated OCD patients
compared to healthy controls, suggesting that a hyperactive
ERN is not related to medication. In a direct comparison of
medicated and unmedicated OCD subjects (Endrass et al., 2008),
the ERN was significantly lower in patients taking medication,
but it is possible that this effect was due to differences in illness
severity between the groups. Given that severely ill patients are
more likely to be on medication, disentangling the potential
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confound between medication use and illness severity remains a
methodological challenge.
In order to examine the effects of chronic medication on error
responses in OCD, we examined ERNs in OCD patients free of
psychotropic medication, OCD patients on SRIs, patient con-
trols on SRIs but without OCD, and healthy control subjects free
of psychotropic medication and psychiatric illness. Any effect of
medication on the ERN that is unrelated to OCD would be
expected to be found in both medicated OCD patients and pa-




Eighty subjects performed the task while electroencephalogram
(EEG) data were acquired. However, two OCD patients were
excluded due to performance on the task; the amount of errors
exhibited by one patient was over 3 standard deviations from the
entire groupmean (4180 errors) and another made fewer than 10
errors. Due to a recent study reporting high internal reliability of
the ERN with 10 errors and moderate reliability with 6 errors
(Olvet & Hajcak, 2009), we also performed all analyses reported
belowwith the inclusion of the subject whomade under 10 errors,
and found results to be unchanged. The final group of 78 subjects
were distributed as follows: 1) 19 OCD patients who were un-
medicated (uOCD), 2) 19 OCD patients taking medication
(mOCD), all of whom were on at least one serotonin reuptake
inhibitor (with the exception of one patient who was taking bu-
proprion), 3) 19 medicated patient controls (mPC), all of whom
were taking at least one serotonin reuptake inhibitor due to prior
history of major depression (in full or partial remission, based on
DSM-IVcriteria), and 4) 21 healthy controls (uHC) free of psy-
chotropic medication and without current or past psychiatric
diagnoses. Demographic and clinical variables of interest were
examined for each group, as shown in Table 1. Unmedicated
OCD and uHC groups were age- and education-matched, as
weremOCD andmPC groups. Group differences in age, years of
education, and scores from the Hamilton Anxiety Rating Scale
(HARS) and Hamilton Depression Rating Scale (HDRS) were
evaluated with separate 2  2 ANOVAs using diagnosis (OCD
vs. control) and medication (unmedicated vs. medicated) as be-
tween-subjects factors. Chi-square tests compared gender (all
groups), the proportion of subjects with a history of depression
(uOCD, mOCD, and mPC groups), the proportion in current
treatment for OCD (uOCD and mOCD groups), and the pro-
portion with a history of hospitalizations for OCD (uOCD and
mOCD groups). Independent samples t-tests were used to com-
pare uOCD andmOCD groups on Yale-Brown Obsessive-Com-
pulsive Scale (YBOCS) scores (Goodman et al., 1989), age of
onset of OCD, and illness duration.
Subjects were recruited through paper advertisements posted
around the local community, online advertisements through the
University of Michigan Health System, and, for OCD patients,
from referrals from the Anxiety Disorders Unit of the University
of Michigan Depression Center/Ambulatory Psychiatry clinics.
Patients in both OCD groups met DSM-IVcriteria for primary
diagnoses of OCD and were free of comorbid psychiatric disor-
ders with the exception of tic disorder and/or specific phobia.
Patients with hoarding as a primary symptom were excluded.
OCD patients were accepted if they had current depressive dis-
order not otherwise specified (NOS) or had histories of major
depressive disorder or dysthymia but were in partial or full re-
mission from their depression (79% ofmOCD patients and 53%
of uOCD patients). While all 19 medicated OCD patients were in
treatment for OCD, with 15 out of the 19 being seen in our
Anxiety clinic, many unmedicated OCD patients (13/19) were
recruited through advertisements and were not in any treatment
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Table 1. Demographic Information
uOCD (n5 19) mOCD (n5 19) mPC (n5 19) uHC (n5 21) Group differences Post-hoc comparisons





Education (years) 14.9 (1.8) 16.1 (2.7) 16.8 (2.1) 16 (2.4) ns
Gender 10 F, 9 M 10 F, 9 M 11 F, 8 M 10 F, 11 M ns






















YBOCS 23.4 (3.5) 21.6 (4.2) ns
Age of onset 12.5 (4.6) 11.7 (5.9) ns
Illness duration (years) 12.5 (8.7) 19.1 (12.3) ns
In current treatment 6/19 19/19 w2 (1)5 19.8,
po.001
History of hospitalizations 3/19 6/19 ns
Note: uOCD5unmedicated OCD; mOCD5medicated OCD; mPC5medicated patient controls; uHC5unmedicated healthy controls. Values in
parentheses represent standard deviations. HARS5Hamilton Anxiety Rating Scale; HDRS5Hamilton Depression Rating Scale; YBOCS5Yale-
Brown Obsessive Compulsive Scale. D5main effect of diagnosis factor; M5main effect of medication factor; D  M5 interaction between
diagnosis and medication factors. Only those effects significant at po.05 are shown, and followed up with post-hoc comparisons using independent-
samples t-tests, except history of depression, which used chi-square tests.
(the 6 patients whowere in treatment were being seen in our clinic
but were not on medication). Despite these differences, the two
OCD groups were similar on many of the demographic and
clinical measures we examined (see Table 1), although medicated
OCD patients were older and had a trend toward longer illness
duration (t(32.4)5 1.9, p5 .067).
Subjects in the mPC group were taking very comparable
medications tomOCD (see Table 2) due to a primary diagnosis of
major depressive disorder that was in full remission (2 subjects
with a history of a single episode and 8 with recurrent episodes)
or partial remission (9 subjects with recurrent episodes). Impor-
tantly, these subjects had no history of OCD and exhibited min-
imal anxiety comorbidity (5 patients total: 1 with panic disorder,
1 with panic disorder and specific phobia, 1 with specific phobia,
and 2 with anxiety disorder NOS), and thus provided partial
control for effects related to histories of depressive episodes
among OCD patients.
All subjects were evaluated by a trained clinician using the
Structured Clinical Interview for DSM-IV (First, Spitzer, Gib-
bon, &Williams, 1996). Depression and anxiety symptoms were
evaluated using Hamilton Ratings Scales for Depression and
Anxiety, respectively, and severity of OC symptoms in OCD
patients was measured using the YBOCS.
Written informed consent as approved by the institutional
review board of the University of Michigan was obtained from
all subjects following a complete description of the study.
Task
We used a modified version of a flanker task in which subjects
pressed one of two buttons based on the identity of a target letter
that was placed in the second, third, or fourth position in a string
of 5 letters. ‘‘Low’’ interference trials were those where both
target and flankers signaled the same button press (‘‘S’’ and ‘‘K’’
lettersFleft button, ‘‘H’’ and ‘‘C’’ lettersFright button), while
‘‘high’’ interference trials elicited errors because the target and
flankers designated opposing responses. Individually tailored re-
sponse deadlines, set at 0.8–1.5 times the mean reaction time
(RT) determined from a practice session, were used to generate
commission error rates between 10–20%. Letter stimuli were
presented on-screen for 300 ms, followed by a blank screen until
the response deadline was achieved. Feedback was presented
immediately following response in order to increase motivation
to perform well and to ensure that subjects maintained their
knowledge of the correct stimulus-response mappings through-
out the experiment. A row of white asterisks were presented for
correct responses, a row of red asterisks were presented for errors
of commission, and a messageF‘‘Too Slow’’Fwas shown if
responses were not within the deadline (i.e., omission error).
Duration of feedback was 700–1300 ms depending on the indi-
vidual subject’s RT on each trial, so that total time between
stimulus presentation and end of feedback presentation was 1800
ms. Following feedback, a blank inter-trial interval (ITI) was
shown for 2000 ms.
The task also varied the incentive value of each trial so that an
error (or correct response) could result in a loss of money (or a
failure to lose), a failure to gain money (or a gain), or no change
in money. Cues showing the amount of money at stake (0, 10, or
50 cents) preceded letter stimuli with durations of 1500–4500 ms
and an average length of 2125ms (in order tomatch a companion
fMRI study). As the incentive was not found to have significant
effects on the ERN, we focus the current report on group effects
on the overall ERN. Money won or lost on each trial was real,
and tallied to provide a bonus at the end of the experiment. A
total of 480 trials (240 low and 240 high interference) were run
over 10 blocks.
In order to determine how subjects evaluated the task and
their performance after completing the experiment, ratings to
three debriefing questions were obtained on a five-point Likert
scale ranging from ‘‘none/not at all’’ (1) to ‘‘always/very’’ (5): 1)
‘‘Did you make any mistakes?,’’ 2) ‘‘Were you ever frustrated
with your performance?,’’ and 3) ‘‘When you made a mistake,
were you flustered? Did you find it hard to get back on track?’’
Data Acquisition and Analysis
Behavioral analyses examined RTon correct trials, commission
error rates, and responses to debriefing questions as dependent
measures in separate 2  2 ANOVAs using diagnosis (OCD vs.
control) and medication status (unmedicated vs. medicated) as
between-subjects factors. Omission errors were excluded from all
analyses.
The EEG was recorded from 26 Ag/AgCl scalp electrodes
(FP1, FP2, AFZ, F7, F3, FZ, F4, F8, FC3, FCZ, FC4, T7, C3,
CZ, C4, T8, CP3, CPZ, CP4, P7, P3, PZ, P4, P8, O1, O2) em-
bedded in a nylon mesh cap (Easy-Cap, Falk Minow Systems,
Inc., http://www.easycap.de) using a left mastoid reference and
forehead ground. Averagemastoid reference was derived off-line
using right mastoid data. The electro-oculogram (EOG) was
recorded from Ag/AgCl electrodes above and below the left eye
and external to the outer canthus of each eye. Impedances were
kept below 10 KO. EEG and EOG were amplified by SYN-
AMPS DC amplifiers (Neuroscan Labs, Sterling, VA) and
filtered on-line from .01 to 100 Hz (half-amplitude cutoffs). Data
were digitized at 500Hz and filtered with a nine-point Chebyshev
II low-pass, zero-phase-shift digital filter (Matlab 7.04;
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Table 2. List of Medications in Medicated OCD (mOCD) and











Citalopram 3 30 1 40
Escitalopram 6 25 9 15
Fluoxetine 4 47.5 2 35
Fluvoxamine 1 250
Paroxetine 1 60
Sertraline 2 162.5 1 100
Venlafaxine 1 300 6 262.5
Benzodiazepines
Alprazolam 3 0.75
Clonazepam 4 0.7 2 0.7








Note: SSRIs5 selective-serotonin reuptake inhibitors; SNRIs5 seroto-
nin-norepinephrine reuptake inhibitors; TCAs5 tricycle antidepres-
sants. All subjects with the exception of one mOCD patient were
taking a serotonin reuptake inhibitor (SSRI or SNRI). SSRIs were taken
by 17/19 mOCDs and 13/19 mPCs, and SNRIs were taken by 1 mOCD
and 6 mPC subjects. Ten mOCD and 8 mPC subjects were taking more
than one medication. Benzodiazepines were taken as needed.
Mathworks, Natick, MA), half-amplitude cutoff at 12 Hz. Oc-
ular movement artifacts were corrected using the algorithm de-
scribed by Gratton, Coles, and Donchin (1983).
In order to correct for the fact that the response-locked ERN
will actually reflect some combination of response and stimulus-
evoked components, we applied a method (Zhang, 1998) that
allows for the unique recovery of the response-locked component
based on the stimulus-locked ERP, response-locked ERP, and
the time between stimulus and response on each trial (reaction
time distribution). The method works as follows. We have ex-
perimentally obtained (a) stimulus-aligned ERP average wave-
form, denoted Fs(t); (b) response-aligned ERP average
waveform, denoted Fr(t); and (c) distribution of reaction times
g(t) across the trials. Suppose the stimulus-aligned and response-
aligned ERP waveforms were generated by two underlying com-
ponent waveforms, a stimulus-locked component (‘‘S-compo-
nent’’), denoted fs(t), and a response-locked component (‘‘R-
component’’), denoted fr(t). By reflecting on how Fs(t) and Fr(t)
were constructed and how fs(t) and fr(t) were defined, the fol-
lowing two mathematical equations were derived:
FsðtÞ ¼ fsðtÞ þ
Z
frðt tÞgðtÞdt ð1Þ
FrðtÞ ¼ frðtÞ þ
Z
fsðtþ tÞgðtÞdt ð2Þ
In convolution notation, they are
FsðtÞ ¼ fsðtÞ þ frðtÞ  gðtÞ ð3Þ
FrðtÞ ¼ frðtÞ þ fsðtÞ  gðtÞ ð4Þ
We can then solve these equations (3) and (4) either by Fourier
transformation (in frequency domain) or by an iterative proce-
dure (in time domain). In practice, due to discrete sampling in
time domain, we can transform equation (3) and (4) into matrix
notation (Yin, Zhang, Tian, & Yao, 2009), and apply singular
value decomposition (SVD) method to the reaction-time distri-
bution to deal with noise introduced by insufficient number of
trials. In this paper, the time domain SVD method (same as
Fourier transform method in nature) was used, by removing/
truncating small eigenvalues (of the reaction time distribution
matrix) to reduce the influence of noise and improve stability.
After recovery of the response-locked waveform, mean am-
plitude was calculated over a window of 20–120 ms post-re-
sponse (identified from grand-averaged waveforms) with a
baseline of 200 to 100 ms prior to response. Three-way ANO-
VAs with diagnosis (OCD vs. control) and medication status
(unmedicated vs. medicated) as between-subjects factors and
trial type (error vs. correct) as a within-subjects factor were per-
formed separately at electrodes FZ and FCZ. Analyses were
performed separately at these two electrodes because inspection
of the topographical distribution of scalp activity indicated that
the peak of the ERN was located at FCZ for control subjects but
anterior to FCZ for OCD patients (see Figure 1). Pearson’s cor-
relations (two-tailed) of error and correct trial amplitudes with
anxiety (HARS) and depression (HDRS), and for OCDpatients,
YBOCS scores, were used to further interrogate effects identified
by the ANOVAs. The mean number of errors per subject con-
tributing to the analysis was 63.94 (SD: 32.77, range: 15–150).
Results
Behavioral
There were no significant differences between the groups for
mean RT on correct trials, although there was a trend for an
interaction between diagnosis and medication (F(1,74)5 3.3,
p5 .072), with unmedicated healthy controls exhibiting the fast-
est RTs and medicated patient controls exhibiting the slowest
RTs (uOCD: 569.2, mOCD: 566.7, mPC: 597.8, uHC: 532.7ms).
Similarly, there were no differences in the mean percentage of
commission errors between groups (uOCD: 12.5%, mOCD:
14%, mPC: 12.9%, uHC: 13.5%).
Analyses of responses to debriefing questions indicated no
main effects or interactions of group factors on subjects’ eval-
uation of the amount ofmistakes that weremade (p4.25 for all).
Interestingly, despite similar performance accuracy, OCD pa-
tients reported being significantly more frustrated with their per-
formance (F(1,74)5 22.1, po.001) and more flustered when
making a mistake (F(1,74)5 21.9, po.001) than control sub-
jects. No other effects were found, with the exception of a trend
toward unmedicated subjects being slightly more flustered when
making a mistake than medicated subjects (F(1,74)5 3.3,
p5 .073).
Electrophysiological
As expected, there was a highly significant main effect of trial
type (error vs. correct) at both electrodes (FZ: F(1,74)5 175,
po.001; FCZ: F(1,74)5 199.9, po.001), such that amplitudes
weremore negative for errors as compared to correct trials. There
were no main effects of group factors (diagnosis or medication
status); however, there was a significant interaction between trial
type and diagnosis (OCD vs. control) at electrode FZ (F(1,
74)5 4.1, p5 .047), indicating that OCD patients exhibited a
greater ERN than control subjects ( 4.0 vs.  2.5 mV,
t(76)5  1.98, p5 .05), with no difference in amplitude on cor-
rect trials (2.7 vs. 2.4 m V, t(76)5 0.38, p5 .71)1 (Figures 1 and
2). Importantly, there were no 2-way interactions between trial
type and medication status or 3-way interactions involving trial
type, medication status, and diagnosis (all ps40.6), indicating
that the presence of chronic medication did not significantly in-
fluence the ERN. No effects of group factors were found at
electrode FCZ.
Among OCD patients, ERN amplitudes were not signifi-
cantly correlated with YBOCS scores (r5 .17, p5 .32) or with
generalized anxiety or depressive symptoms (HARS: r5 .13,
p5 .43, HDRS: r5 .10, p5 .57) (Figure 3). By contrast, among
control subjects, therewas a significant correlation between ERN
amplitude and HARS (r5  .35, p5 .027) and HDRS
(r5  .35, p5 .026), such that greater symptom severity was
associated with an increased ERN. As can be seen fromFigure 3,
these relationships were found within both uHC and mPC
groups for HARS (r5  .49, p5 .023 and r5  .41, p5 .082,
respectively) and HDRS (r5  .39, p5 .081, and r5  .46,
p5 .050, respectively) scores. Correct trial amplitudes were not
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1When removing the one mOCD patient not taking a serotonin re-
uptake inhibitor (i.e., buproprion), the interaction remained significant,
F(1,73)5 7, p5 .034.
correlated with symptom severity measures for either OCD pa-
tients or controls.
Discussion
Previous studies have identified an increased ERN in patients
withOCD (Endrass et al., 2008; Gehring et al., 2000; Johannes et
al., 2001), yet it has been unclear whether the use of serotonin
reuptake inhibitors among OCD patients may be influencing this
finding given evidence linking serotonergic functioning to the
ERN (Fallgatter et al., 2004; Jocham & Ullsperger, 2009).
Methodologically, it is difficult to separate primary markers of a
disorder from secondary phenomena related to treatment effects
and comorbidity. As such, it may be particularly advantageous
to compare treated and untreated patient groups matched on
symptom severity, along with a treated ‘‘control’’ group with a
diagnosis that is highly comorbid with the primary disorder, as
was done in the current investigation. Our results indicated that
OCD patients exhibited an increased ERN irrespective of med-
ication use, and that medication use in patient controls was not
associated with any elevation in the ERN compared to healthy
controls. This extends previous findings of no effect of acute
administration of selective-serotonin reuptake inhibitor (SSRI)
on the ERN in healthy controls (de Bruijn, Sabbe, Hulstijn,
Ruigt, & Verkes, 2006) to include chronic administration of SRIs
in a patient population. The current findings suggest that ERN
hyperactivity in OCD is not an epiphenomenon of SSRI admin-
istration, and that if serotonergic activity does impact the ERN
(Fallgatter et al., 2004; Jocham&Ullsperger 2009), it may not be
a simple effect of reuptake inhibition.
Does an increased ERN simply reflect greater anxiety and/or
depression in OCD patients rather than being specific to OCD?
Previous studies have indeed found greater ERNs associated
with generalized anxiety (Hajcak, McDonald, & Simons, 2003)
and major depressive disorder (Chiu & Deldin, 2007; Holmes &
Pizzagalli, 2008). Our results indicated that, while OCD patients
exhibited more anxiety and depressive symptoms (in addition to
OC symptoms) than either control group, their level of these
symptoms did not predict ERN amplitude. Intriguingly,
within both control groups, greater anxiety and depression were
associated with increased ERN amplitude. It is possible that the
ERN is normally influenced by levels of negative affect, but that
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Figure 1. Topographic maps of ERN amplitude. Error activity shows a medial frontal focus, with the peak of activity in OCD patients located slightly
anterior to that of control subjects. Scale represents mean activity in mV between 20 and 120 ms post error response.
Figure 2. Error and correct trial waveforms for OCD patients and control subjects. OCD patients (blue lines) exhibited greater amplitude for errors
(solid) but not correct trials (dashed) as compared to control subjects (black lines). Bar graph shows the amplitude of the difference wave
(errorFcorrect) in each group. uHC5unmedicated healthy controls; mPC5medicated patient controls; uOCD5unmedicated OCD patients;
mOCD5medicated OCD patients.
in OCD this mechanism is overshadowed by a disorder-specific
abnormality that is not related to the severity of generalized
anxiety or depressive symptoms.
Although symptoms of depression were related to an increased
ERN in unmedicated healthy and medicated patient controls, a
diagnosis of major depressive disorder in remission was not asso-
ciated with an overall enhancement of the ERN in themPC group.
Such a distinction between effects of current versus prior depressive
symptomatology on the ERN may help explain inconsistencies
among previous studies examining the ERN in depression, which
have identified no differences between remitted depressed patients
and controls (Ruchsowet al., 2004, 2006), but an increasedERN in
moderately depressed patients in a current depressive episode (Chiu
& Deldin, 2007; Holmes & Pizzagalli, 2008).
Our data indicated that ERNs were similarly increased for
medicated and unmedicatedOCDgroups, whichwas unexpected
given previous findings of a reduction in cingulate and orbito-
frontal hyperactivity after a course of medication in OCD pa-
tients (Perani et al., 1995; Saxena et al., 1999). One possibility is
that the medicated group was actually more severely ill prior to
their initiationof treatment, andwouldhave showngreaterYBOCS
scores and ERNs than unmedicated patients had they been tested in
an untreated state. However, as ERN amplitudes were not corre-
lated with YBOCS scores in the OCD group, our data do not
support the hypothesis that the increased ERN found in OCD is a
function of OC symptom severity. Rather, this result provides sup-
port for the notion that ERNhyperactivitymay be a traitmarker of
OCD that is not sensitive to fluctuations in symptom severity and
does not decrease in response to treatment, consistent with a recent
study reporting no change in ERN hyperactivity among children
with OCD after treatment with cognitive behavioral therapy (Ha-
jcak, Franklin, Foa, & Simons, 2008).
While the ERNwas robust for all groups at electrodes FZ and
FCZ, the difference between OCD patients and controls was
greatest at the more anterior electrode FZ. This is likely due to
the slightly anterior topography of the ERN in OCD patients as
compared to control subjects, which may have psychological
significance. Although the ERN is typically thought to have a
source in posterior/dorsal regions of medial frontal cortex/ante-
rior cingulate gyrus (Dehaene et al., 1994; van Veen & Carter,
2002), it has also been shown to correlate with activity in an-
terior/rostral regions of medial frontal cortex (Mathalon, Whit-
field, & Ford, 2003). Anterior MFC is involved in emotion and
social processing (Amodio & Frith, 2006; Bush, Luu, & Posner,
2000; Steele & Lawrie, 2004), and it stands to reason that the
relative contribution of posterior versus anterior regions ofMFC
to the ERN may, in fact, vary based upon the psychological
reaction to making an error. In our study, OCD patients were
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Figure 3.Correlations between ERN amplitude and symptoms of generalized anxiety and depression. Significant relationships were found in the control
group but not in the OCD group. Trend lines are shown for correlations in all control subjects (solid black) and all OCD patients (solid blue), and for
each group separately (unmedicated healthy controls: short dashed light gray; medicated patient controls: long dashed dark gray; unmedicated OCD
patients: short dashed light blue; medicated OCD patients: long dashed dark blue).
more frustrated with their performance and more flustered when
making an error than control subjects. It is possible that the
emergence of the group difference at the more anterior site is due
to a greater contribution of anterior regions ofMFC to the ERN
in OCD patients, in relation to their heightened emotional re-
action. Although speculative, such a hypothesis is consistent with
previous fMRI data identifying error-related hyperactivation of
anterior MFC in OCD patients (Fitzgerald et al., 2005).
There are several limitations to the current study that suggest
avenues for future research. First, performance feedback pro-
vided on a trial-by-trial basis was used to increase motivation,
but may have reduced the response-locked signal by shifting at-
tention away from the response toward the feedback. As it is
conceivable that error feedbackwould bemore salient, and hence
divert more attention, than correct feedback, this feature of the
study may have lead to a disproportionate reduction in the ERN
compared to correct trial ERPs. However, given that there were
no differences in accuracy between groups, this is unlikely to
account for the greater ERN in OCD patients. Second, although
mPCs and mOCDs were nearly all taking some form of SRI
medication, we did not control for the concomitant use of ben-
zodiazepines or non-SRI antidepressant medication. The med-
icated groups had similar proportions of subjects taking these
additional medications, however, and greater use of benzodiaze-
pines among OCD patients cannot explain their exaggerated
ERN relative to controls, since benzodiazepines have been as-
sociated with a reduced ERN (de Bruijn, Hulstijn, Verkes, Ruigt,
& Sabbe, 2004; Riba, Rodrı́guez-Fornells, Münte, & Barbanoj,
2005). Third, among SRI types, there was a greater proportion of
SNRIs being taken by mPCs than mOCD patients. Yet, as nor-
epinephrine release has been shown to increase the ERN (Riba,
Rodrı́guez-Fornells, Morte, Münte, & Barbanoj, 2005), this,
too, would work against the finding of exaggerated the ERN in
the OCD patients. Sample sizes were too small to segregate
medicated subjects based on SSRI, SNRI, and additional med-
ication use, somore detailed analysis of medication effects on the
ERN will require replication with a larger sample. Subjects in-
cluded here were not taking antipsychotic medications, but con-
sidering that these are sometimes used as adjunctive therapy in
OCD and can reduce the ERN (de Bruijn et al., 2006), future
studies should seek to track or exclude their use as well.
In sum, our results indicate that OCD patients have exagger-
ated ERNs that are not due to SRI medication use. The data also
show that greater severity of generalized anxiety and depressive
symptoms is associated with increased ERNs among control
subjects, but that these symptoms do not account for ERN
hyperactivity in OCD patients. Instead, our results suggest that
an increased ERNmay be a neural endophenotype of OCD that
does not fluctuate with symptom severity or decrease with phar-
macological treatment. Future studies would benefit from com-
paring trait and state influences on ERN hyperactivity across
different psychiatric disorders, and by examining genetic influ-
ences on the ERN in OCD, in order to further explore these
effects.
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